ASX-listed digital health firm ResApp Health has received the go-ahead for a trial of its smartphone app to screen for chronic obstructive pulmonary disease (COPD) at the Geraldton Regional Aboriginal Medical Service in Western Australia.
The study will recruit up to 200 subjects over a six-month period who will undergo a full clinical and spirometric assessment. Results from ResApp’s COPD screening app will be compared to the final clinical diagnosis.
